Order Article Reprints

Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, Cescon D, Chia S. Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”. Current Oncology. 2023; 30(5):5050-5053. https://doi.org/10.3390/curroncol30050381

Rayson, Daniel, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, and Stephen Chia. 2023. "Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”" Current Oncology 30, no. 5: 5050-5053. https://doi.org/10.3390/curroncol30050381

Rayson, D., Gandhi, S., Joy, A. A., Brezden-Masley, C., Gelmon, K. A., Sehdev, S., Cescon, D., & Chia, S. (2023). Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”. Current Oncology, 30(5), 5050-5053. https://doi.org/10.3390/curroncol30050381